HNRNPU
HNRNPU (Heterogeneous nuclear ribonucleoprotein U) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Burkitt lymphoma.
Overview
DNA- and RNA-binding protein involved in several cellular processes such as nuclear chromatin organisation, telomere-length regulation, transcription, mRNA alternative splicing and stability, Xist-mediated transcriptional silencing and mitotic cell progression. Plays a role in the regulation of interphase large-scale gene-rich chromatin organisation through chromatin-associated RNAs (caRNAs) in a transcription-dependent manner, and thereby maintains genomic stability. Required for the localisation of the long non-coding Xist RNA on the inactive chromosome X (Xi) and the subsequent initiation and maintenance of X-linked transcriptional gene silencing during X-inactivation.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · HNRNPU (Heterogeneous nuclear ribonucleoprotein U) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Burkitt lymphoma.
- 1 · What it is
HNRNPU (Heterogeneous nuclear ribonucleoprotein U) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Burkitt lymphoma.
- 2 · What goes wrong in cancer
DNA- and RNA-binding protein involved in several cellular processes such as nuclear chromatin organisation, telomere-length regulation, transcription, mRNA alternative splicing and stability, Xist-mediated transcriptional silencing and mitotic cell progression.
- 3 · How drugs use it
No product in this corpus aims at HNRNPU yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:5048 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q00839 (protein name, function text, keywords and locations (REST API)); CIViC gene HNRNPU (1 evidence items, 0 assertions, 1 variants; diseases: Burkitt Lymphoma (GraphQL API, CC0))
Biology
DNA- and RNA-binding protein involved in several cellular processes such as nuclear chromatin organisation, telomere-length regulation, transcription, mRNA alternative splicing and stability, Xist-mediated transcriptional silencing and mitotic cell progression. Plays a role in the regulation of interphase large-scale gene-rich chromatin organisation through chromatin-associated RNAs (caRNAs) in a transcription-dependent manner, and thereby maintains genomic stability. Required for the localisation of the long non-coding Xist RNA on the inactive chromosome X (Xi) and the subsequent initiation and maintenance of X-linked transcriptional gene silencing during X-inactivation. Plays a role as a RNA polymerase II (Pol II) holoenzyme transcription regulator. Promotes transcription initiation by direct association with the core-TFIIH basal transcription factor complex for the assembly of a functional pre-initiation complex with Pol II in a actin-dependent manner. Blocks Pol II transcription elongation activity by inhibiting the C-terminal domain (CTD) phosphorylation of Pol II and dissociates from Pol II pre-initiation complex prior to productive transcription elongation. Location: Nucleus; Nucleus matrix; Chromosome; Nucleus speckle (UniProt). Locus 1q44 (HGNC).
- Burkitt lymphoma: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"HNRNPU" OR ABSTRACT:"HNRNPU" OR TITLE:"heterogeneous nuclear ribonucleoprotein U" OR ABSTRACT:"heterogeneous nuclear ribonucleoprotein U" OR TITLE:"Heterogeneous nuclear ribonucleoprotein U" OR ABSTRACT:"Heterogeneous nuclear ribonucleoprotein U" OR TITLE:"SAF-A" OR ABSTRACT:"SAF-A" OR TITLE:"FLJ37978" OR ABSTRACT:"FLJ37978" OR TITLE:"FLJ30202" OR ABSTRACT:"FLJ30202") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about HNRNPU, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetCHD8
Shares Burkitt lymphoma, CIViC.
- TargetEIF4A1
Shares Burkitt lymphoma, CIViC.
- TargetWNK1
Shares Burkitt lymphoma, CIViC.
- TargetBMP7
Shares Burkitt lymphoma, CIViC.
- TargetRFX7
Shares Burkitt lymphoma, CIViC.
- TargetGNAI2
Shares Burkitt lymphoma, CIViC.
- TargetTFAP4
Shares Burkitt lymphoma, CIViC.
- TargetSIN3A
Shares Burkitt lymphoma, CIViC.